Rückert, 2021 - Google Patents
Immunological basis of abscopal antitumor responses induced by combination of distinct radiotherapy fractionation schedules with autologous tumor vaccines and …Rückert, 2021
View PDF- Document ID
- 14525838002659051108
- Author
- Rückert M
- Publication year
External Links
Snippet
Ionizing radiation is commonly used in radiotherapy (RT) for the local treatment of solid tumors to kill cancer cells and to stop tumor progression. Meanwhile, RT is also known to have immune-stimulatory properties by causing immunogenic tumor cell death turning …
- 206010028980 Neoplasm 0 title abstract description 429
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hossain et al. | Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression | |
| US20210228633A1 (en) | Combination immune therapy and cytokine control therapy for cancer treatment | |
| JP6884155B2 (en) | Combination immunotherapy and cytokine control therapy for cancer treatment | |
| Zhao et al. | TNF signaling drives myeloid-derived suppressor cell accumulation | |
| Spaner et al. | A phase I/II trial of oxidized autologous tumor vaccines during the “watch and wait” phase of chronic lymphocytic leukemia | |
| Kwan et al. | Antigen-presenting cell–derived complement modulates graft-versus-host disease | |
| JP6858128B2 (en) | Combination of immunotherapy and cytokine control therapy for cancer treatment | |
| Zhang et al. | Low-dose gemcitabine treatment enhances immunogenicity and natural killer cell-driven tumor immunity in lung cancer | |
| Cao et al. | Interleukin 12 stimulates ifn-γ–mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance | |
| Saito et al. | Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1–specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature | |
| Albring et al. | Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression | |
| Nelson et al. | Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression | |
| US20210179687A1 (en) | Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer | |
| EP3277313B1 (en) | Agents and compositions for eliciting an immune response | |
| Tan et al. | Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression | |
| Schaafsma et al. | VISTA targeting of T-cell quiescence and myeloid suppression overcomes adaptive resistance | |
| Hu et al. | A promising sword of tomorrow: human γδ T cell strategies reconcile allo-HSCT complications | |
| Musso et al. | Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas | |
| Müller et al. | Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche | |
| Harada et al. | Soluble factors derived from neuroblastoma cell lines suppress dendritic cell differentiation and activation | |
| Mariotti et al. | Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection | |
| Pan et al. | PD-1 antibody and ruxolitinib enhances graft-versus-lymphoma effect without increasing acute graft-versus-host disease in mice | |
| Rückert | Immunological basis of abscopal antitumor responses induced by combination of distinct radiotherapy fractionation schedules with autologous tumor vaccines and checkpoint inhibition | |
| WO2020171138A1 (en) | Peripheral blood biomarker for evaluating anti-tumor immune effect of radiation therapy | |
| Onyshchenko et al. | Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models |